Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase

British Journal of Haematology

Volumn 164, Issue 1, 2014, Pages 61-72

  Yang, Xiaochuan ^a   Sexauer, Amy ^a   Levis, Mark ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukaemia; Bone marrow stroma; Extracellular regulated kinase; FLT3 ITD; Quizartinib

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; FMS LIKE TYROSINE KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SORAFENIB; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW STROMA CELL; CANCER RESISTANCE; CELL CONTACT; CELL CYCLE ARREST; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE DUPLICATION; HUMAN; HUMAN CELL; IC 50; INTERNAL TANDEM DUPLICATION; MALE; MIDDLE AGED; PRIORITY JOURNAL; STROMA CELL;

ACUTE MYELOID LEUKAEMIA; BONE MARROW STROMA; EXTRACELLULAR REGULATED KINASE; FLT3-ITD; QUIZARTINIB;

APOPTOSIS; BONE MARROW CELLS; CELL COMMUNICATION; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 84889582194     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12599     Document Type: Article

References (42)

1. Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J.J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M. & Cortes, J.E. (2011) Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 96, 62-68.
2. Brinchmann, J.E. (2008) Expanding autologous multipotent mesenchymal bone marrow stromal cells. Journal of the Neurological Sciences, 265, 127-130.
3. Brown, A.P., Carlson, T.C., Loi, C.M. & Graziano, M.J. (2007) Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemotherapy and Pharmacology, 59, 671-679.
4. Chamberlain, G., Fox, J., Ashton, B. & Middleton, J. (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25, 2739-2749.
5. Choudhary, C., Olsen, J.V., Brandts, C., Cox, J., Reddy, P.N., Bohmer, F.D., Gerke, V., Schmidt-Arras, D.E., Berdel, W.E., Muller-Tidow, C., Mann, M. & Serve, H. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Molecular Cell, 36, 326-339.
6. Coffer, P.J., Koenderman, L. & de Groot, R.P. (2000) The role of STATs in myeloid differentiation and leukemia. Oncogene, 19, 2511-2522.
7. DeAngelo, D.J., Stone, R.M., Heaney, M.L., Nimer, S.D., Paquette, R.L., Klisovic, R.B., Caligiuri, M.A., Cooper, M.R., Lecerf, J.M., Karol, M.D., Sheng, S., Holford, N., Curtin, P.T., Druker, B.J. & Heinrich, M.C. (2006) Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 108, 3674-3681.
8. Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.M., Bello, C.L., Allred, R., Manning, W.C., Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E. & Hossfeld, D.K. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105, 986-993.
9. James, J., Pratz, K., Stine, A., Apuy, J., Insko, D.E., Armstrong, R.C., Zarrinkar, P.P., Small, D., Wierenga, W. & Levis, M. (2008) Clinical pharmacokinetics and FLT3 phosphorylation of AC220, a highly potent and selective inhibitor of FLT3. Blood, 112, 2637a.
10. Kaneko, S., Motomura, S. & Ibayashi, H. (1982) Differentiation of human bone marrow-derived fibroblastoid colony forming cells (CFU-F) and their roles in haemopoiesis in vitro. British Journal of Haematology, 51, 217-225.
11. Levis, M. & Small, D. (2003) FLT3: ITDoes matter in leukemia. Leukemia, 17, 1738-1752.
12. Levis, M., Pham, R., Smith, B.D. & Small, D. (2004) In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood, 104, 1145-1150.
13. Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., Godley, L.A., Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Wiktor-Jedrzejczak, W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Bensen-Kennedy, D.M., Small, D. & Smith, B.D. (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 117, 3294-3301.
14. Levis, M., Perl, A., Dombret, H., Dohner, H., Steffen, B., Rousselot, P., Martinelli, G., Estey, E., Burnett, A., Gammon, G., Trone, D., Leo, E. & Cortes, J. (2012) Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts), 120, 673a.
15. Manabe, A., Murti, K.G., Coustan-Smith, E., Kumagai, M., Behm, F.G., Raimondi, S.C. & Campana, D. (1994) Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood, 83, 758-766.
16. Matsuo, Y., MacLeod, R.A., Uphoff, C.C., Drexler, H.G., Nishizaki, C., Katayama, Y., Kimura, G., Fujii, N., Omoto, E., Harada, M. & Orita, K. (1997) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia, 11, 1469-1477.
17. Meads, M.B., Gatenby, R.A. & Dalton, W.S. (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews Cancer, 9, 665-674.
18. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W.E. & Serve, H. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96, 3907-3914.
19. Ohashi, K., Sequist, L.V., Arcila, M.E., Moran, T., Chmielecki, J., Lin, Y.L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., Aoe, K., Toyooka, S., Kiura, K., Fernandez-Cuesta, L., Fidias, P., Yang, J.C., Miller, V.A., Riely, G.J., Kris, M.G., Engelman, J.A., Vnencak-Jones, C.L., Dias-Santagata, D., Ladanyi, M. & Pao, W. (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 109, E2127-E2133.
20. Parmar, A., Marz, S., Rushton, S., Holzwarth, C., Lind, K., Kayser, S., Dohner, K., Peschel, C., Oostendorp, R.A. & Gotze, K.S. (2011) Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. Cancer Research, 71, 4696-4706.
21. Piloto, O., Wright, M., Brown, P., Kim, K.T., Levis, M. & Small, D. (2007) Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood, 109, 1643-1652.
22. Pratz, K. & Levis, M. (2008) Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leukaemia & Lymphoma, 49, 852-863.
23. Pratz, K.W., Cortes, J., Roboz, G.J., Rao, N., Arowojolu, O., Stine, A., Shiotsu, Y., Shudo, A., Akinaga, S., Small, D., Karp, J.E. & Levis, M. (2009) A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood, 113, 3938-3946.
24. Pratz, K.W., Sato, T., Murphy, K.M., Stine, A., Rajkhowa, T. & Levis, M. (2010a) FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 115, 1425-1432.
25. Pratz, K.W., Cho, E., Levis, M.J., Karp, J.E., Gore, S.D., McDevitt, M., Stine, A., Zhao, M., Baker, S.D., Carducci, M.A., Wright, J.J., Rudek, M.A. & Smith, B.D. (2010b) A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia, 24, 1437-1444.
26. Ravandi, F., Cortes, J.E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M.Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., Pierce, S.R., Brandt, M., Byrd, A., Bekele, B.N., Pratz, K., Luthra, R., Levis, M., Andreeff, M. & Kantarjian, H.M. (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology, 28, 1856-1862.
27. Roberts, P.J. & Der, C.J. (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-3310.
28. Rocnik, J.L., Okabe, R., Yu, J.C., Lee, B.H., Giese, N., Schenkein, D.P. & Gilliland, D.G. (2006) Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood, 108, 1339-1345.
29. Sato, T., Yang, X., Knapper, S., White, P., Smith, B.D., Galkin, S., Small, D., Burnett, A. & Levis, M. (2011) FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood, 117, 3286-3293.
30. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909-1918.
31. Sexauer, A., Perl, A., Yang, X., Borowitz, M., Gocke, C., Rajkhowa, T., Thiede, C., Frattini, M., Nybakken, G.E., Pratz, K., Karp, J., Smith, B.D. & Levis, M. (2012) Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood, 120, 4205-4214.
32. Sison, E.A. & Brown, P. (2011) The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Review of Hematology, 4, 271-283.
33. Smith, B.D., Bambach, B.J., Vala, M.S., Barber, J.P., Enger, C., Brodsky, R.A., Burke, P.J., Gore, S.D. & Jones, R.J. (1998) Inhibited apoptosis and drug resistance in acute myeloid leukaemia. British Journal of Haematology, 102, 1042-1049.
34. Smith, B.D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K.M., Dauses, T., Allebach, J. & Small, D. (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 103, 3669-3676.
35. Smith, C.C., Wang, Q., Chin, C.S., Salerno, S., Damon, L.E., Levis, M.J., Perl, A.E., Travers, K.J., Wang, S., Hunt, J.P., Zarrinkar, P.P., Schadt, E.E., Kasarskis, A., Kuriyan, J. & Shah, N.P. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485, 260-263.
36. Stone, R.M., DeAngelo, D.J., Klimek, V., Galinsky, I., Estey, E., Nimer, S.D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., Fox, E.A., Neuberg, D., Clark, J., Gilliland, D.G. & Griffin, J.D. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 105, 54-60.
37. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., Cooper, Z.A., Chapman, P.B., Solit, D.B., Ribas, A., Lo, R.S., Flaherty, K.T., Ogino, S., Wargo, J.A. & Golub, T.R. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487, 500-504.
38. Weisberg, E., Wright, R.D., McMillin, D.W., Mitsiades, C., Ray, A., Barrett, R., Adamia, S., Stone, R., Galinsky, I., Kung, A.L. & Griffin, J.D. (2008) Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics, 7, 1121-1129.
39. Wilson, A. & Trumpp, A. (2006) Bone-marrow haematopoietic-stem-cell niches. Nature Reviews Immunology, 6, 93-106.
40. Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D.P., Koeppen, H., Merchant, M., Neve, R. & Settleman, J. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487, 505-509.
41. Zarrinkar, P.P., Gunawardane, R.N., Cramer, M.D., Gardner, M.F., Brigham, D., Belli, B., Karaman, M.W., Pratz, K.W., Pallares, G., Chao, Q., Sprankle, K.G., Patel, H.K., Levis, M., Armstrong, R.C., James, J. & Bhagwat, S.S. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 114, 2984-2992.
42. Zeng, Z., Shi, Y.X., Samudio, I.J., Wang, R.Y., Ling, X., Frolova, O., Levis, M., Rubin, J.B., Negrin, R.R., Estey, E.H., Konoplev, S., Andreeff, M. & Konopleva, M. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood, 113, 6215-6224.